Global trends in the use of stem cell transplantation for AML

Molly Tokaz, MD, Fred Hutchinson Cancer Center, Seattle, WA, shares the results of a study investigating global trends in stem cell transplantation (SCT) for acute myeloid leukemia (AML). The study reported an overall increase in the use of allogeneic SCT (alloSCT) and a decrease in the use of autologous SCT (autoSCT). The increase in SCT was most pronounced in low and middle-income countries (LMICs). Nevertheless, the SCT utilization rate (STUR) was below expected in all parts of the world, especially in LMICs. In Europe and North America, most transplants were from unrelated donor sources, while related donors were more commonly used in the rest of the world. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.